Novartis AG (NVS)
NYSE: NVS
· Real-Time Price · USD
124.19
2.10 (1.72%)
At close: Aug 15, 2025, 3:59 PM
124.00
-0.15%
After-hours: Aug 15, 2025, 07:33 PM EDT
Novartis Revenue Breakdown
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|
| Top 20 products Revenue | 32.14B | 32.66B | 29.92B | 28.65B | 26.95B |
| Top 20 products Revenue Growth | -1.61% | +9.19% | +4.43% | +6.31% | n/a |
| Rest of portfolio Revenue | 9.16B | 9.33B | 9.1B | 9.07B | 7.95B |
| Rest of portfolio Revenue Growth | -1.84% | +2.57% | +0.32% | +14.12% | n/a |
| Anti Infectives sold under Sandoz name Revenue | 777M | 707M | 694M | 784M | n/a |
| Anti Infectives sold under Sandoz name Revenue Growth | +9.90% | +1.87% | -11.48% | n/a | n/a |
| Total anti-infectives net sales Revenue | 1.2B | 1.1B | n/a | n/a | n/a |
| Total anti-infectives net sales Revenue Growth | +9.09% | n/a | n/a | n/a | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|
| China Revenue | 3.13B | 3.05B | 2.57B | 2.44B | 852M |
| China Revenue Growth | +2.49% | +18.62% | +5.36% | +186.62% | n/a |
| Country Of Domicile Revenue | 970M | 873M | 2.44B | 4.12B | 2.71B |
| Country Of Domicile Revenue Growth | +11.11% | -64.25% | -40.73% | +52.31% | n/a |
| France Revenue | 2.26B | 2.52B | 4.52B | 2.66B | 4.18B |
| France Revenue Growth | -10.51% | -44.18% | +70.11% | -36.52% | n/a |
| Germany Revenue | 4.28B | 4.87B | 2.8B | 16.28B | 3.17B |
| Germany Revenue Growth | -12.16% | +73.68% | -82.78% | +413.73% | n/a |
| Japan Revenue | 2.21B | 2.68B | 800M | n/a | 22.17B |
| Japan Revenue Growth | -17.82% | +235.37% | n/a | n/a | n/a |
| Other Countries Revenue | 20.05B | 20.81B | 19.04B | n/a | 17.56B |
| Other Countries Revenue Growth | -3.62% | +9.30% | n/a | n/a | n/a |
| United States Revenue | 17.65B | 16.82B | 16.48B | n/a | n/a |
| United States Revenue Growth | +4.96% | +2.03% | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 3.44M | 3.06B | 3.5B | 3.13B | 3.09B | 2.84B | 3.44B | 3.09B | 3.69B | 3.44B | 3.75B | 3.41B | 3.58B | 3.51B | 3.98B | 3.62B | 3.75B | 3.53B | 3.92B | 3.42B | 3.37B | 3.49B | 3.9B | 3.55B | 3.58B | 3.33B | 4.4B | 3.26B | 4.19B | 3.92B | 4.04B | 3.68B | 3.81B | 3.47B | 3.84B | 3.4B | 3.65B | 3.31B | 3.88B | 3.46B | 3.62B | 3.28B |
| Selling, General, and Administrative Revenue Growth | -99.89% | -12.65% | +11.71% | +1.39% | +8.84% | -17.54% | +11.42% | -16.14% | +7.06% | -8.11% | +9.79% | -4.69% | +1.96% | -11.87% | +10.14% | -3.62% | +6.38% | -10.07% | +14.77% | +1.51% | -3.38% | -10.73% | +10.03% | -1.00% | +7.66% | -24.39% | +35.05% | -22.23% | +6.88% | -2.92% | +9.87% | -3.36% | +9.62% | -9.54% | +12.88% | -6.82% | +10.41% | -14.93% | +12.19% | -4.26% | +10.21% | n/a |
| Research and Development Revenue | 2.73M | 2.37B | 2.84B | 2.39B | 2.28B | 2.23B | 2.57B | 3.92B | 2.53B | 2.79B | 2.44B | 2.74B | 2.5B | 2.32B | 2.41B | 2.38B | 2.4B | 2.35B | 2.33B | 2.15B | 2.44B | 2.06B | 2.85B | 2.2B | 2.05B | 2.3B | 2.4B | 2.15B | 2.28B | 2.12B | 2.5B | 2.24B | 2.06B | 2.17B | 2.58B | 2.22B | 2.19B | 2.04B | 2.47B | 2.19B | 2.21B | 2.07B |
| Research and Development Revenue Growth | -99.88% | -16.75% | +18.81% | +5.10% | +2.06% | -13.13% | -34.60% | +55.38% | -9.59% | +14.41% | -10.75% | +9.53% | +7.67% | -3.69% | +1.22% | -0.83% | +2.08% | +0.77% | +8.71% | -12.09% | +18.50% | -27.80% | +29.74% | +7.22% | -10.79% | -4.17% | +11.74% | -5.67% | +7.36% | -15.27% | +11.75% | +8.58% | -4.93% | -16.06% | +16.19% | +1.55% | +7.30% | -17.44% | +12.88% | -0.73% | +6.72% | n/a |
| Sales and Marketing Revenue | 3.44M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 3.46B | 3.17B | 3.24B | 2.99B | 3.25B | 2.94B | 3.07B | 2.74B | 3.17B | 2.89B | 3.02B | 2.69B |
| Sales and Marketing Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -100.00% | +9.34% | -2.22% | +8.40% | -7.92% | +10.26% | -4.01% | +11.89% | -13.67% | +9.86% | -4.18% | +12.08% | n/a |